Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$3.40 USD
-0.04 (-1.16%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $3.42 +0.02 (0.59%) 7:36 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.40 USD
-0.04 (-1.16%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $3.42 +0.02 (0.59%) 7:36 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates
by Zacks Equity Research
Dare Bioscience (DARE) delivered earnings and revenue surprises of 366.67% and 96.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis
by Zacks Equity Research
Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of -63.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
by Zacks Equity Research
Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.
New Strong Sell Stocks for December 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.